相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells
Hassan Dianat-Moghadam et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Review of cancer treatment with immune checkpoint inhibitors
Christiane Thallinger et al.
WIENER KLINISCHE WOCHENSCHRIFT (2018)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome
Fevzi Firat Yalniz et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Natural killer cells target and differentiate cancer stem-like cells/undifferentiated tumors: strategies to optimize their growth and expansion for effective cancer immunotherapy
Kawaljit Kaur et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
NK cell therapy for hematologic malignancies
Rohtesh S. Mehta et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Tumor-derived exosomes, microRNAs, and cancer immune suppression
Michael W. Graner et al.
SEMINARS IN IMMUNOPATHOLOGY (2018)
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
Norbert Vey et al.
Oncotarget (2018)
NK Cell-Specific CDK8 Deletion Enhances Antitumor Responses
Agnieszka Witalisz-Siepracka et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2018)
Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target
Muhammad Zaeem Noman et al.
ONCOIMMUNOLOGY (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma
Phu Hung Nguyen et al.
CLINICAL CANCER RESEARCH (2017)
Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy
Jesus I. Luna et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
NK cell heparanase controls tumor invasion and immune surveillance
Eva M. Putz et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Y. Liu et al.
ONCOGENE (2017)
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
Congcong Zhang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation
Stefan O. Ciurea et al.
BLOOD (2017)
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Lucia Fernandez et al.
CLINICAL CANCER RESEARCH (2017)
Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours
Mira M. Shenouda et al.
BREAST CANCER RESEARCH (2017)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Petra S. A. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
Repression of GSK3 restores NK cell cytotoxicity in AML patients
Reshmi Parameswaran et al.
NATURE COMMUNICATIONS (2016)
Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection
Rohtesh S. Mehta et al.
VIRULENCE (2016)
Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Yaewon Yang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity
Eva Maria Putz et al.
ONCOIMMUNOLOGY (2016)
Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
John Pradeep Veluchamy et al.
PLOS ONE (2016)
Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner
L. Fernandez et al.
CANCER LETTERS (2015)
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
Don M. Benson et al.
CLINICAL CANCER RESEARCH (2015)
A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors
Antonio Perez-Martinez et al.
CYTOTHERAPY (2015)
NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype
Erik Ames et al.
JOURNAL OF IMMUNOLOGY (2015)
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer
Naoyuki Sakamoto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors
Andrea Gras Navarro et al.
FRONTIERS IN IMMUNOLOGY (2015)
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Bo Yuan Huang et al.
PLOS ONE (2015)
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma
Jessica Rueff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
Effect of tumor cells and tumor microenvironment on NK-cell function
Massimo Vitale et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde et al.
HAEMATOLOGICA (2014)
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
Ana Stojanovic et al.
JOURNAL OF IMMUNOLOGY (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin et al.
LANCET ONCOLOGY (2014)
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Magdalena Paolino et al.
NATURE (2014)
Clinical utility of natural killer cells in cancer therapy and transplantation
David A. Knorr et al.
SEMINARS IN IMMUNOLOGY (2014)
Interleukin-17D Mediates Tumor Rejection through Recruitment of Natural Killer Cells
Timothy O'Sullivan et al.
CELL REPORTS (2014)
Induction of split anergy conditions natural killer cells to promote differentiation of stem cells tnrough cell-cell contact and secreted factors
Han-Ching Tseng et al.
FRONTIERS IN IMMUNOLOGY (2014)
Are natural killer cells superior CAR drivers?
Hans Klingemann
ONCOIMMUNOLOGY (2014)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+T and NK cells and improves survival
Richard K. Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy
Q. Zhou et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
Christian A. Gerdes et al.
CLINICAL CANCER RESEARCH (2013)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
Natural killer cell biology: An update and future directions
Kerry S. Campbell et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
Joachim Koch et al.
TRENDS IN IMMUNOLOGY (2013)
The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity
Joanna Baginska et al.
FRONTIERS IN IMMUNOLOGY (2013)
Innate Lymphoid Cells: Emerging Insights in Development, Lineage Relationships, and Function
Hergen Spits et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
Saar Gill et al.
BLOOD (2012)
IL-2-or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
Maria P. Roberti et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
Javier Rodriguez et al.
EUROPEAN JOURNAL OF CANCER (2012)
Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors
Antonio Perez-Martinez et al.
EXPERIMENTAL HEMATOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity
C. Kellner et al.
LEUKEMIA (2012)
Natural killer cells act as rheostats modulating antiviral T cells
Stephen N. Waggoner et al.
NATURE (2012)
A restricted cell population propagates glioblastoma growth after chemotherapy
Jian Chen et al.
NATURE (2012)
Human NK cell lytic granules and regulation of their exocytosis
Konrad Krzewski et al.
FRONTIERS IN IMMUNOLOGY (2012)
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Antonio Curti et al.
BLOOD (2011)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst et al.
CLINICAL CANCER RESEARCH (2011)
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
Melissa A. Geller et al.
CYTOTHERAPY (2011)
Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients
Eric A. Engels et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Barbara Molon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Natural Killer Cells and Solid Tumors
Ana Stojanovic et al.
JOURNAL OF INNATE IMMUNITY (2011)
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Cyril Fauriat et al.
BLOOD (2010)
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
Niklas K. Bjorkstrom et al.
BLOOD (2010)
CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset
Sandra Lopez-Verges et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
Vanessa Deschoolmeester et al.
BMC IMMUNOLOGY (2010)
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
Eleni G. Iliopoulou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
Jeffrey E. Rubnitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking
Min Fang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Hypoxic Tumor Cell Modulates Its Microenvironment to Enhance Angiogenic and Metastatic Potential by Secretion of Proteins and Exosomes
Jung Eun Park et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells
Petter Brodin et al.
BLOOD (2009)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagne et al.
BLOOD (2009)
HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
S. Nguyen et al.
BONE MARROW TRANSPLANTATION (2009)
Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions
Jennifer K. Mulligan et al.
HUMAN IMMUNOLOGY (2009)
A Role for cis Interaction between the Inhibitory Ly49A Receptor and MHIC Class I for Natural Killer Cell Education
Anick Chalifour et al.
IMMUNITY (2009)
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
Cameron S. Brandt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Enhanced In Vivo Growth of Lymphoma Tumors in the Absence of the NK-Activating Receptor NKp46/NCR1
Gili G. Halfteck et al.
JOURNAL OF IMMUNOLOGY (2009)
NK cell education: not an on-off switch but a tunable rheostat
Petter Brodin et al.
TRENDS IN IMMUNOLOGY (2009)
Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: A prospective study
Luis F. Porrata et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Immunomodulatory drugs Revlimid (R) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Dan Zhu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Marco Wendel et al.
CANCER RESEARCH (2008)
Direct and natural killer cell-mediated antitumor effects of low-dose Bortezomib in hepatocellular carcinoma
Sorin Armeanu et al.
CLINICAL CANCER RESEARCH (2008)
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
S. Arai et al.
CYTOTHERAPY (2008)
NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
Esther Moga et al.
EXPERIMENTAL HEMATOLOGY (2008)
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Nadia Guerra et al.
IMMUNITY (2008)
Signaling defects in anti-tumor T cells
Alan B. Frey et al.
IMMUNOLOGICAL REVIEWS (2008)
Human tumor-derived exosomes down-modulate NKG2D expression
Aled Clayton et al.
JOURNAL OF IMMUNOLOGY (2008)
Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer
G. Esendagli et al.
LUNG CANCER (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Ronald J. Buckanovich et al.
NATURE MEDICINE (2008)
HLA alleles determine differences in human natural killer cell responsiveness and potency
Surl Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Tumor immune escape by the loss of homeostatic chemokine expression
Anclor Pivarcsi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Cancer stem cells as mediators of treatment resistance in brain tumors: Status and controversies
Per O. Sakariassen et al.
NEOPLASIA (2007)
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration
Paul Proost et al.
BLOOD (2007)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Self-tolerance of natural killer cells
David H. Raulet et al.
NATURE REVIEWS IMMUNOLOGY (2006)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
Licensing of natural killer cells by host major histocompatibility complex class I molecules
S Kim et al.
NATURE (2005)
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo
K Wiemann et al.
JOURNAL OF IMMUNOLOGY (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Natural killer cells infiltrating colorectal cancer and MHC class I expression
MH Sandel et al.
MOLECULAR IMMUNOLOGY (2005)
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response
WL Gluck et al.
CLINICAL CANCER RESEARCH (2004)
The dynamic life of natural killer cells
WM Yokoyama et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer
FR Villegas et al.
LUNG CANCER (2002)
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
A Diefenbach et al.
NATURE (2001)
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
K Imai et al.
LANCET (2000)
分享论文
